Clinical investigation
Brain
Five-year survivors of brain metastases: A single-institution report of 32 patients

https://doi.org/10.1016/j.ijrobp.2006.05.015Get rights and content

Purpose: To report on 32 patients who survived ≥5 years from brain metastases treated at a single institution.

Methods and Materials: The records of 1288 patients diagnosed with brain metastases between 1973 and 1999 were reviewed. Patients were treated with whole-brain radiation therapy (WBRT), surgery, and/or stereotactic radiosurgery (SRS). Thirty-two (2.5%) ≥5-year survivors were identified. Factors contributing to long-term survival were identified.

Results: Median survival was 9.3 years for ≥5-year survivors. Seven of these patients lived ≥10 years. Female gender was the only patient characteristic that correlated with better survival (p = 0.0369). When these patients were compared with <5-year survivors, age <65 years (p = 0.0044), control of the primary at diagnosis (p = 0.0052), no systemic disease (p = 0.0012), recursive partitioning analysis (RPA) Class 1 (p = 0.0002 with Class 2; p = 0.0022 with Class 3), and single brain metastasis (p = 0.0018) were associated with long-term survival in the univariate logistic regression model. In the multivariate model, RPA Class 1 compared with Class 2 (OR = 0.39, p = 0.0196), surgery (OR = 0.16, p < 0.0001), and SRS (OR = 0.41, p = 0.0188) were associated with long-term survival.

Conclusions: For patients with good prognostic factors such as young age, good RPA characteristics and single metastasis, treatment with surgery or SRS offers the best chance for long-term survival.

Introduction

Brain metastasis is the most common neurologic complication of cancer and occurs in 30% of cancer patients (1). The incidence has been increasing as patients are surviving longer from their primary disease. Unfortunately, the diagnosis of brain metastasis still carries a poor prognosis with a median survival of 4 months. Even patients with a single brain metastasis treated aggressively with surgical resection and whole-brain radiation therapy (WBRT) have a median survival of 40 weeks (2). The Radiation Therapy Oncology Group (RTOG) applied a recursive partitioning analysis (RPA) to the data from three randomized trials of brain metastases to group prognostic factors associated with survival (3). RPA Class 1 patients (Karnofsky Performance Status [KPS] of 70 or greater, controlled primary disease, age younger than 65 years old, and no extracranial metastases) have a median survival of 7.1 months, but RPA Class 3 patients (KPS <70) have a median survival of 2.3 months. All other patients are RPA Class 2 (KPS of ≥70, but uncontrolled primary disease, age 65 years or more, or extracranial metastases) and have a median survival of 4.2 months.

Despite advances in surgery, radiation therapy and chemotherapy, long-term survival is very rare. Two percent of patients with brain metastasis live 5 years or more (4, 5). Ten-year survivors are even more rare, with 33 patients described in the literature (5, 6). We reviewed our experience with such long-term patients by querying from a large institutional database of more than 1300 patients for those who had a minimum potential follow-up of 5 years. The goal of this study is to identify factors that contribute to long-term survival.

Section snippets

Methods and materials

The records of 1,316 patients diagnosed with brain metastases between 1973 and 1999 were reviewed and entered into an Institutional Review Board–approved database. The year 1999 was selected as a cutoff point to allow for a minimum potential follow-up of 5 years. Of these, 1275 (97%) patients were known to have expired. Thirteen (1%) were still alive. Twenty-eight (2%) were lost to follow-up; therefore, they were excluded from the analysis. This left 1,288 patients with adequate follow-up to

Results

The characteristics of all brain metastases patients used in this study (n = 1,288) are in Table 1. The characteristics of the 5 years or more survivors are also shown for comparison. The median survival for all brain metastases patients was 6.0 months. Figure 1 shows the Kaplan-Meier survival curve for all brain metastases patients. Various characteristics were compared using the Kaplan-Meier method to determine if any factors influenced survival (Table 2). Age younger than 65 years, control

Discussion

Survival from brain metastasis is poor. The median survival in our group of patients was 6.0 months. Factors that predicted for survival in this study, which confirm the results of other studies, include age younger than 65 years, control of the primary, and lack of systemic disease (3). Other factors that were prognostic for survival include single brain metastasis at diagnosis and longer interval from diagnosis of their primary to diagnosis of their brain metastasis. Patients with single

Conclusion

Long-term survival is rare, but possible from brain metastases. For patients with good prognostic factors such as young age, good RPA characteristics, and single lesions, aggressive treatment that includes upfront surgery and/or SRS may offer the best chance of long-term survival. Female gender also appears to influence long-term survivorship, but the cause of this remains unclear. Further research, particularly in regards to the biology of these tumors, may identify other characteristics that

Cited by (49)

  • Brain Metastases and Neoplastic Meningitis

    2019, Abeloff’s Clinical Oncology
  • Identifying Better Surgical Candidates among Recursive Partitioning Analysis Class 2 Patients who Underwent Surgery for Intracranial Metastases

    2014, World Neurosurgery
    Citation Excerpt :

    Patients with an increased number of these preoperative variables had statistically significant poorer survival, regardless of perioperative treatment. Patients with metastatic disease have disparate survival times (2-6, 11, 13-15). In general, as for other types of malignancies, surgery, and more aggressive therapies are usually offered to patients with better anticipated survival, but are withheld from patients with poor prognoses (10, 12, 16, 24).

  • Management of Brain Metastases: Surgery, Radiation, or Both?

    2012, Hematology/Oncology Clinics of North America
    Citation Excerpt :

    Historically the presence of brain metastases was considered to be a poor prognostic indicator.2,4 However, recent studies suggest that patients with intracranial metastases are surviving longer,5,6 which is largely due to improvements in systemic therapies and is supported by more aggressive approaches to intracranial therapy. The current treatment paradigm for intracranial metastases reflects a multidisciplinary approach that combines both surgery and radiation.

View all citing articles on Scopus
View full text